

1           The effects of the infarct volume on cytokines and  
2           immune status in patients with acute ischemic stroke

3           **Short title: The immune status of patients with acute cerebral infarction is**  
4           **related to the infarct volume**

5           Author: Xingqi Su<sup>1</sup>, Lingmin Zhao<sup>1</sup>, Di Ma<sup>1\*</sup>, Jiulin You<sup>1</sup>, Liangshu Feng<sup>1</sup>, Jing  
6           wang<sup>1</sup>, YuLei Hao<sup>1</sup>, XinYu Wang<sup>1</sup>, JiaChun Feng<sup>1</sup>

7  
8  
9           <sup>1</sup> Affiliation: Bethune First Hospital, Jilin University, Changchun, China

10          \* Corresponding author: Di Ma, LiJuan Wang

11          Email:

12          madi2017@jlu.edu.cn (M.D)

13          wanglj66@jlu.edu.cn (W.Lj)

14  
15          **Abstract**

16          **Objective:** To investigate and analyze the effects of the infarct volume on cytokines  
17          and immune status in patients with acute ischemic stroke. **Methods:** Patients with acute  
18          ischemic stroke that presented within 72 h of onset from October 2017 to October 2019  
19          were enrolled. Patients with severe cerebral infarction (large-area cerebral infarction)  
20          (n=34) were enrolled and categorized as group A; Additionally, 33 patients with non-  
21          large-area cerebral infarction with matching baseline characteristics (sex and age) to  
22          group A were included in group B. We measured IL-2, IL-4, IL-6, IL-10, IL-17A, TNF-  
23           $\alpha$ , and IFN- $\gamma$  levels in serum using a cytometric bead array. In addition, we compared  
24          the absolute value of lymphocytes (LYM#), lymphocyte percentage (LYM%),

**NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.**

25 neutrophil/lymphocyte ratio (NLR), cytokine levels, and immune status indicators  
26 (IFN- $\gamma$  IL-4 ratio, TNF- $\alpha$ /IL-4 ratio, and TNF- $\alpha$ /IL-10 ratio) between groups A and B,  
27 and evaluated the effect of infarct size on inflammatory factors and immune status.  
28 **Results:** Compared with group B, the LYM# and LYM% in group A were significantly  
29 lower, and the NLR and cytokines (IL-2, IL-4, IL-6, IL-10, IL-17A, TNF- $\alpha$ , and IFN-  
30  $\gamma$ ) levels were significantly higher. TNF- $\alpha$ /IL-4 ratio was significantly lower, and the  
31 IFN- $\gamma$ /IL-4 ratio (P=0.09) and TNF- $\alpha$ /IL-10 ratio (P=0.146) in group A demonstrated a  
32 decreasing trend although not significant. **Conclusions:** The immune status of patients  
33 with acute cerebral infarction is related to the infarct volume; patients with large-area  
34 cerebral infarction are more likely to develop immunosuppression.

35

## 36 Key words

37 Acute cerebral infarction, immunity, inflammation, cytokines, inflammatory  
38 cells, infarct volume

39

## 40 1. Introduction

41 According to the all-cause mortality statistics of the World Health Organization  
42 (WHO), stroke is the second leading cause of death globally, accounting for 87%[1],  
43 and its high disability rate significantly increases the social burden. Because immunity  
44 is crucial in cerebral infarction and, in turn, is regulated by it, the immune mechanism  
45 has become a target that may benefit clinical treatment and has attracted increasing  
46 interest from researchers.

47 Notably, immunity is crucial in the occurrence, progression, and outcome of  
48 ischemic stroke. The basic pathology of atherosclerotic cerebral infarction is

49 atherosclerosis. Various immune cells, including lymphocytes and mononuclear  
50 macrophages, are involved in the formation of atherosclerotic plaques and the rupture  
51 of unstable plaques[2,3], an important cause of atherosclerotic cerebral infarction[4].  
52 Immunity contributes to the pathogenesis of cerebral infarction and affects  
53 prognosis[5–8]. After local cerebral infarction, astrocytes and microglia, which are  
54 involved in the release of cytokines and chemokines[9], are rapidly activated, attract  
55 immune cells from the peripheral circulation to the ischemic area, and participate in  
56 inflammatory damage to the brain tissue[10]. In addition, in the recovery from chronic  
57 cerebral infarction, the immune status affects the brain tissue microenvironment,  
58 regulates neurogenesis[11,12] and angiogenesis[13], and affects the autoimmune  
59 response to brain tissue antigens after stroke, mediating the long-term prognosis[5,6].  
60 Notably, as a stress event, ischemic stroke regulates systemic immunity through the  
61 sympathetic nervous system and the hypothalamus-pituitary-adrenal axis, which is an  
62 important mechanism of post-stroke immunosuppression, leading to increase mortality  
63 of patients with acute cerebral infarction [7,8,16-19]. We know that the size of different  
64 infarcts also affects the treatment and prognosis of acute ischemic  
65 stroke,(PMED: 28665171)In this study, we investigate and analyze the effects of the  
66 infarct volume on cytokines and immune status in patients with acute ischemic  
67 stroke.This enables the clinicians to make informed decisions in selecting  
68 immunotherapy approaches and tailor rehabilitation strategies to optimize patient  
69 outcomes by considering different infarct sizes.

70

## 71 **2. Materials and methods**

### 72 **2.1 Research objects and samples**

73 Inclusion criteria:

- 74 1. Patients with acute ischemic stroke presenting with an onset time of  $\leq 72$  h in  
75 the Department of Neurology of the First Hospital of Jilin  
76 University(Changchun,China) from October 2017 to October 2019.
- 77 2. Patients who voluntarily participated in the study.
- 78 3. Patients aged 18–80 years old, regardless of sex.

79 Exclusion criteria:

- 80 1. Intracranial artery dissection, aneurysm, vascular inflammatory diseases,  
81 vascular malformations, and other neurological diseases.
- 82 2. Patients who have undergone thrombolysis or thrombectomy.
- 83 3. Patients with or suspected cerebral embolism.
- 84 4. Abnormal liver and kidney function; AST or ALT 3 times higher than the upper  
85 limit of normal value; creatinine clearance rate of  $< 0.6$  mL/s; blood creatinine  
86 level  $> 265$   $\mu\text{mol/L}$ .
- 87 5. Patients with autoimmune diseases, who have received immunotherapy, or with  
88 malignant tumors.
- 89 6. Patients with severe trauma or have undergone major surgery recently.

90 Sample collection:

91 Peripheral blood (2–3 mL) of the patients were collected immediately after  
92 admission using a coagulation blood collection tube. After centrifugation (4 °C, 3000  
93 r/min, 5 min), the supernatant (serum samples) was collected and cryopreserved at -  
94 80 °C.

## 95 **2.2 Reagents and equipment:**

96 BD FACS Calibur flow cytometer (BD Company, USA); low-temperature high-  
97 speed centrifuge (Heraeus Sepaech, Germany); low-temperature refrigerator (Haier

98 Company, Qingdao, China); BD™ Cytometric Bead Array (CBA) human  
99 Th1/Th2/Th17 kit (BD Company, USA); BD™ Cytometric Bead Array (CBA) Human  
100 Soluble Protein Master Buffer kit, (BD Company, USA).

## 101 **2.3 Determination of cytokines in serum samples by CBA**

### 102 **method**

103 The BD™ Cytometric Bead Array (CBA) human Th1/Th2/Th17 kit was used to  
104 determine the cytokine (IL-2, IL-6, IL-4, IL-10, IL-17A, IFN- $\gamma$ , TNF- $\alpha$ ) levels in each  
105 serum sample according to the manufacturer's instructions.

## 106 **2.4 Experimental group**

107 A total of 67 patients presenting with an onset time of 72 h were included in this  
108 study; patients with large-area cerebral infarction were included in the large-area  
109 cerebral infarction group and categorized as group A. A total of 34 patients, including  
110 patients with anterior circulation infarction and posterior circulation infarction, were  
111 included. For anterior circulation infarction, the maximum diameter of the infarct  
112 was  $>3$  cm (25 participants), and regarding posterior circulation infarction, the  
113 maximum infarction cross-section was  $>1/3$  of the brainstem (9 participants).

114 Additionally, 33 patients with non-large-area cerebral infarction with matching  
115 sex and age with Group A were included in the non-large-area cerebral infarction group  
116 and categorized as Group B, including patients with anterior circulation infarction and  
117 posterior circulation infarction. For anterior circulation infarctions, the largest infarct  
118 diameter was  $<3$  cm (27 participants), and for posterior circulation infarctions, the  
119 largest brainstem infarct area was  $<1/3$  of the cross-sectional area (6 participants).

## 120 **2.5 Statistical analysis and graph**

121 Statistical analysis was performed using IBM SPSS Statistics version 25.0 (IBM

122 Corp., Armonk, N.Y., USA), and GraphPad Prism version 7 (GraphPad Software, Inc.,  
123 La Jolla, CA, USA) was used for graphing. The counted data were presented as the  
124 number of cases (n) and percentages (%). Measurement data with normal distribution  
125 are presented as  $\bar{x} \pm s$  and measurement data that are not normally distributed are  
126 presented as the median and quartile M (Q25–Q75). For counting data, the Chi-square  
127 test ( $\chi^2$  test) was used to compare groups. For the comparison between the two groups  
128 of measurement data, the t-test was used for normally distributed data, and the  
129 nonparametric rank-sum test (Mann–Whitney U test) was used for non-normal  
130 distribution. For the comparison between the three groups of measurement data, a one-  
131 way analysis of variance (ANOVA) was used for the normal distribution, and the  
132 variance was uniform. The LSD-t test was used for the pairwise comparison of the mean  
133 between the groups.

134 The groups showed statistically significant differences, with a P-value of <0.05  
135 indicating statistical significance; for pairwise comparison of the mean between the  
136 groups, the statistical difference was based on the unadjusted P-value <0.017 and the  
137 adjusted P-value <0.05.

### 138 **3. Results**

139 We compared the expression levels of various cytokines, including IL-2, IL-4, IL-  
140 6, IL-10, and IL17A, in the large-area infarction group (group A) and the non-large-  
141 area infarction group (group B) based on the same baseline level. Furthermore, we  
142 compared the absolute lymphocyte value (LYM#), lymphocyte ratio lymphocyte  
143 percentage (LYM%), neutrophil/lymphocyte ratio (NLR), IFN- $\gamma$ /IL-4 ratio, TNF- $\alpha$ /IL-  
144 4 ratio, and TNF- $\alpha$ /IL-10 ratio between groups A and B.

145 The results indicated the following: (1) The cytokine levels in group A were  
146 significantly higher than in group B, as shown in Table 2 and Fig 1. These differences

147 were considered statistically significant;  $P < 0.05$ . (2) Group A exhibited significantly  
148 lower LYM# and LYM% than group B, and the NLR was significantly higher. These  
149 findings are presented in Table 3 and Fig 2 and showed statistically significant  
150 differences. (3) The TNF- $\alpha$ /IL-4 ratio in group A was significantly lower than in group  
151 B, which showed a statistically significant difference. The TNF- $\alpha$ /IL-10 ratio and IFN-  
152  $\gamma$ /IL-4 ratio in group A demonstrated a decreasing trend but showed no statistically  
153 significant differences (Table 4 and Fig 3).

154

155 **Table 1. Baseline data between patients in group A and group B.**

Baseline	Group A	Group B	P-value
Sex, Male (n, %)	19 (55.88%)	24 (72.7%)	0.151
Female (n, %)	15 (44.12%)	9 (27.3%)	
Hypertension (n, %)	23 (67.65%)	26 (78.79%)	0.304
Diabetes (n, %)	10 (29.42%)	10 (30.30%)	0.936
Smoking history (n, %)	14 (41.17%)	13 (39.39%)	0.882
Age (years)	63.5 (57–69)	62.5 (56.25–69)	0.768
LDL-C (mmol/L)	3.06 (2.72–4.34)	2.9 (2.29–3.86)	0.075
Hcy ( $\mu$ mol/L)	14.45 (10.93–19.65)	15.3 (13.4–20.8)	0.166
Fasting blood glucose (mmol/L)	5.84 (5.23–7.93)	5.71 (4.96–6.61)	0.349
NIHSS score	13 (11–16.25)	4 (3–8)	0.000

156

157

158 **Table 2. Serum cytokine levels of patients of group A and group B.**

Cytokine level	Group A	Group B	U-value	P-value
<b>IL-6 (pg/mL)</b>	32.35 (9.69–56.60)	9.81 (3.09–28.60)	320.00	0.003
<b>IL-4 (pg/mL)</b>	4.02 (3.45–4.76)	0.58 (0.31–0.80)	27.00	0.000
<b>IL-2 (pg/mL)</b>	1.96 (1.75–2.19)	0.55 (0.32–0.98)	84.50	0.000
<b>IL-17A (pg/mL)</b>	8.15 (6.30–9.66)	3.25 (1.37–5.08)	142.00	0.000
<b>IFN-<math>\gamma</math> (pg/mL)</b>	2.58 (2.30–2.99)	0.61 (0.22–0.95)	13.00	0.000
<b>TNF<math>\alpha</math> (pg/mL)</b>	2.63 (2.23–3.15)	1.71 (0.80–2.82)	284.00	0.001
<b>IL-10 (pg/mL)</b>	3.43 (2.66–4.52)	1.31 (0.89–2.46)	169.00	0.000

159 Mann–Whitney U test was used. The cytokine levels in group A were significantly  
160 higher than in group B.

161

162

163 **Fig 1. Serum cytokine levels of groups A and group B patients.**

164 \*\* P<0.01.

165

166 **Table 3. LYM#, LYM%, and NLR between group A and group B.**

Indicators	Group A	Group B	U-value	P-value
<b>LYM# (<math>\times 10^9</math>)</b>	1.41 (1.05–1.79)	1.76 (1.43–2.35)	324.50	0.003
<b>LYM%</b>	0.14 (0.08–0.22)	0.26 (0.21–0.33)	214.00	0.000
<b>NLR</b>	5.27 (3.26–10.79)	2.61 (1.73–3.36)	204.00	0.000

167 Mann–Whitney U test was used. The LYM# and LYM% of the large-area group (group  
168 A) were significantly lower than those of the non-large-area group (group B), while the  
169 NLR of group A was significantly higher than that of group B.

170

171



172 **Fig 2. LYM#, LYM%, NLR of group A and group B.**

173 \*\* P<0.01

174

175 **Table 4. Indicators of immune status of patients in group A and group B.**

Indicators	Group A	Group B	U-value	P-value
<b>TNF-<math>\alpha</math>/IL-4</b>	0.69 (0.54–0.83)	2.50 (1.62–5.99)	137.00	0.000
<b>TNF-<math>\alpha</math>/IL-10</b>	0.80 (0.53–1.12)	1.05 (0.53–3.06)	445.00	0.146
<b>IFN-<math>\gamma</math>/IL-4</b>	0.66 (0.52–0.82)	1.07 (0.40–2.06)	426.00	0.090

176 Mann–Whitney U test was used. The TNF- $\alpha$ /IL-4 ratio in group A was significantly  
177 lower than in group B; the TNF- $\alpha$ /IL-10 and IFN- $\gamma$ /IL-4 ratios in group A showed a  
178 downward trend.

179

180 **Fig 3. Immune status of patients in group A and group B.**

181 \*\* P<0.01.

182

## 183 **4. Discussion**

184 Ischemic stroke is a common cerebrovascular disease; it causes irreversible brain  
185 tissue damage. The complex pathological mechanism includes excitatory glutamate  
186 toxicity, calcium overload, oxidative stress, and inflammatory damage.

187 Inflammatory reaction is crucial in brain tissue injury following infarction. The  
188 immune state regulates local pathophysiological changes and significantly affects the  
189 outcome of ischemic tissues. The proinflammatory state aggravates local injury;  
190 however, the anti-inflammatory state protects the local brain tissue, promotes the  
191 removal of necrotic cells, and prevents further damage. Inflammation of the central  
192 nervous system and peripheral systemic immunity are closely linked and reflect the

193 delicate and ingenious integrity of the human body. For example, the blood-brain  
194 barrier (BBB) is compromised after cerebral infarction and peripheral immune cells  
195 invade the brain tissue. The Th cells that invade the central nervous system secrete  
196 several cytokines and interact with microglia to initiate microglial polarization [14,15];  
197 this affects the degree and outcome of the local brain tissue damage.

198 The relationship between the nervous and immune systems is such that the  
199 immune system affects the pathophysiological changes of cerebral infarction and is, in  
200 turn, affected by cerebral infarction events, such as immunosuppression after stroke.  
201 The underlying mechanism is not fully understood. Post-stroke immunosuppression is  
202 a self-protective mechanism for suppressing central inflammation; however, it alters  
203 peripheral immune status and further affects the prognosis in patients with acute  
204 cerebral infarction[7–8].

205 Considering the role of immune factors in the course of cerebral infarction,  
206 investigating the immune mechanisms has increasingly attracted the interest of  
207 researchers. The body's immunity is affected by several factors, and some related  
208 factors can be controlled artificially; therefore, the immune mechanism may be a  
209 potential clinical treatment target. In this study, we evaluated the levels of various  
210 cytokines, including IL-2, IL-6, TNF- $\alpha$ , IFN- $\gamma$ , IL-4, IL-10, and IL-17A in patients  
211 presenting with acute cerebral infarction within 72 h of onset, and calculated the INF-  
212  $\gamma$ /IL-4, TNF- $\alpha$ /IL-4, and TNF- $\alpha$ /IL-10 ratios. The IFN- $\gamma$ /IL-4 ratio indicates the balance  
213 between the subpopulations of helper T cells, reflecting the relative function between  
214 the Th1 and Th2 subpopulations. IFN- $\gamma$  is an essential proinflammatory cytokine  
215 secreted by Th1-type cells, while IL-4 is a relatively specific cytokine of Th2-type cells  
216 and exerts an anti-inflammatory effect. The initial Th cells, Th0 cells, are regulated by  
217 several factors and differentiated into subpopulations. The most significant factor is the

218 type and level of cytokines and the balance between each cytokine[20]. Therefore, the  
219 IFN- $\gamma$ /IL-4 ratio is of great significance. Furthermore, the mononuclear macrophage  
220 system is divided into M1- and M2-type responses and is regulated by the Th1/Th2  
221 immune status. Proinflammatory M1-type macrophages are polarized by binding to  
222 lipopolysaccharide (LPS) or Th1-type cytokines (such as IFN- $\gamma$ ), producing  
223 proinflammatory cytokines including IL-1 $\beta$ , IL- 23, TNF- $\alpha$ ; anti-inflammatory M2  
224 macrophages are polarized by Th2-related cytokines, such as IL-4 and IL-13, and  
225 secrete anti-inflammatory cytokines such as IL-10 and TGF- $\beta$ [21], promoting tissue  
226 healing and inflammation resolution[22]. Therefore, the M1/M2 type immune response  
227 can be evaluated by the TNF- $\alpha$ /IL-4 ratio and the TNF- $\alpha$ /IL-10 ratio.

228 In this study, by collecting laboratory test results, imaging data, and medical  
229 history, we discovered that the levels of various inflammatory factors and immune  
230 status in patients with acute cerebral infarction were affected by the infarct size.

231 The infarct size significantly affects the immune system. While several studies  
232 have focused on the effect of infarct size on adaptive immune function impairment, we  
233 explored its effects on the immune status and the balance between proinflammatory and  
234 anti-inflammatory responses. Fluctuations in various cytokine levels in the peripheral  
235 circulation can reflect changes in peripheral immunity following stroke. Our results  
236 showed that the levels of cytokines (IFN- $\gamma$ , TNF- $\alpha$ , IL-2, IL-4, IL-6, IL10, IL-17A)  
237 were significantly higher in the group with large-area cerebral infarction than those in  
238 non-large-area cerebral infarction group; however, the extent of increase varied for each  
239 cytokine. Furthermore, compared to the baseline-matched non-large cerebral infarction  
240 group, the absolute value and percentage of lymphocytes decreased significantly in  
241 patients with large cerebral infarctions; however, the NLR was significantly higher in  
242 the large-area cerebral infarction group. Neutrophils are crucial in innate immunity, and

243 the NLR reflects the degree of immune disorder. A higher NLR indicated a greater  
244 degree of adaptive immunity impairment. Our findings suggest that patients with large-  
245 area cerebral infarctions have more impaired adaptive immune functions, and the  
246 relative levels of cytokines affect the immune status (adaptive immunity). Additionally,  
247 we calculated the IFN- $\gamma$ /IL-4, TNF- $\alpha$ /IL-4, and TNF- $\alpha$ /IL-10 ratios. The data showed  
248 that the TNF- $\alpha$ /IL-4 ratio was significantly decreased in the group with large-area  
249 cerebral infarction, indicating a more anti-inflammatory balance. Notably, the IFN-  
250  $\gamma$ /IL-4 and TNF- $\alpha$ /IL-10 ratios were decreased, suggesting a shift towards an anti-  
251 inflammatory response in patients with severe infarction.

252 The immune response is involved throughout cerebral infarction and plays an  
253 important role in the process of disease transformation with a great degree of variation.  
254 Therefore, it is a potential target for improving the prognosis and outcomes of  
255 neurological function. However, at present, there is no systematic research on the  
256 effects of the infarct volume on cytokines in patients with acute ischemic stroke, and  
257 there is a lack of a deeper understanding of the impact of the immune status on clinical  
258 adverse events. Cerebral infarction is a complex disease; several conditions induce it,  
259 and the pathological mechanism after its onset is complicated.

260 This study collected first-hand clinical information on patients and systematically  
261 analyzed that severity of infarction may affect the serum cytokine levels and immune  
262 status of patients with acute cerebral infarction, and explored how it regulates immunity.  
263 This study provides valuable clinical data for related fields and enables the clinicians  
264 to make informed decisions in selecting immunotherapy approaches and tailor  
265 rehabilitation strategies to optimize patient outcomes by considering different infarct  
266 sizes.

267

268

269

## 270 **Acknowledgment**

271 We are highly thankful to Bethune First Hospital of Jilin University, Professor Ms. Wang, and  
272 Professor Ms.Ma for guiding us to finalize this article.Thanks to Xingqi Su, Lingmin Zhao,Julin  
273 You,LiangShu Feng,LiChong Zhu,Ying Chen,YuLei Hao,XinYu Wang ,JiaChun Feng,the above  
274 authors for their joint efforts.

275

## 276 **Funding**

277 None.

278

## 279 **Data availability**

280 The data that support the findings of this study are available from the corresponding author  
281 upon reasonable request.

282

## 283 **ethics statements**

284 The Ethics Committee of the First Hospital of Jilin University reviewed and approved the study,  
285 ensuring that it adhered to ethical principles and guidelines for human subject research. The  
286 approval number AF-IRB-032-02 indicates that the study has undergone thorough ethical scrutiny  
287 and met the necessary requirements.

288

289 The participants were provided with detailed information about the study, including its purpose,  
290 procedures, potential risks and benefits, confidentiality measures, and their rights as participants.  
291 They were given ample time to ask questions and clarify any concerns before voluntarily signing  
292 the consent form.

293

294 The written informed consent form documented the participant's agreement to participate in  
295 the study and their understanding of the information provided. It also stated that they could  
296 withdraw from the study at any time without penalty.

297

298 To ensure confidentiality, the consent forms were securely stored and accessible only to the  
299 research team. Any identifying information was anonymized or coded to protect the participants'  
300 privacy.The research team will continue to prioritize the welfare and rights of the participants  
301 throughout the study, maintaining ethical standards and promptly addressing any concerns that  
302 may arise.

303           Patients with acute ischemic stroke that presented within 72 h of onset from October 2017 to  
304   October 2019 were enrolled.


---

## 305 References




- 306 1.Pan J, Li X, Peng Y. Remote ischemic conditioning for acute ischemic stroke: dawn in the  
307 darkness. *Reviews in the Neurosciences*. 2016;27.
- 308 2.Fernandez DM, Rahman AH, Fernandez NF, Chudnovskiy A, Giannarelli C. Single-cell immune  
309 landscape of human atherosclerotic plaques. *Nature Medicine*. 2019;25(10).
- 310 3.Pakzad B, Rajae E, Shahrabi S, Mansournezhad S, Saki N. T-Cell Molecular Modulation  
311 Responses in Atherosclerosis Anergy. *Laboratory Medicine*. 2020;(16).
- 312 4.Yi X, Zhu L, Sui G, Li J, Bao S. Inflammation and Endothelial Function Relevant Genetic  
313 Polymorphisms and Carotid Plaque in Chinese Population. *Journal of Atherosclerosis and*  
314 *Thrombosis*. 2020;27(9).
- 315 5.Korn T, Kallies A. T cell responses in the central nervous system. *Nature Reviews Immunology*.  
316 2017;17(3):179-94. doi: 10.1038/nri.2016.144.
- 317 6.Becker KJ, Kalil AJ, Tanzi P, Zierath DK, Savos AV, Gee JM, et al. Autoimmune responses to  
318 the brain after stroke are associated with worse outcome. *Stroke*. 2011;42(10):2763-9. Epub  
319 20110728. doi: 10.1161/strokeaha.111.619593.
- 320 7.Ren H, Liu X, Wang L, Gao Y. Lymphocyte-to-Monocyte Ratio: A Novel Predictor of the  
321 Prognosis of Acute Ischemic Stroke. *J Stroke Cerebrovasc Dis*. 2017;26(11):2595-  
322 602.Epub20170826.doi:10.1016/j.jstrokecerebrovasdis.2017.06.019.
- 323 8.Nam KW, Kim TJ, Lee JS, Kwon HM, Lee YS, Ko SB, et al. High Neutrophil-to-Lymphocyte  
324 Ratio Predicts Stroke-Associated Pneumonia. *Stroke*. 2018;49(8):1886-92. doi:  
325 10.1161/strokeaha.118.021228.
- 326 9.Wang Y, Zhang JH, Sheng J, Shao A. Immunoreactive Cells After Cerebral Ischemia. *Front*  
327 *Immunol*.2019;10:2781.Epub 20191126. doi:10.3389/fimmu.2019.02781.
- 328 10.Jian Z, Liu R, Zhu X, Smerin D, Zhong Y, Gu L, et al. The Involvement and Therapy Target of  
329 Immune Cells After Ischemic Stroke. *Front Immunol*. 2019;10:2167. Epub 20190911. doi:  
330 10.3389/fimmu.2019.02167.
- 331 11.Saino O, Taguchi A, Nakagomi T, Nakano-Doi A, Kashiwamura S, Doe N, et al.  
332 Immunodeficiency reduces neural stem/progenitor cell apoptosis and enhances neurogenesis in the  
333 cerebral cortex after stroke. *J Neurosci Res*. 2010;88(11):2385-97. doi: 10.1002/jnr.22410.
- 334 12.Butovsky O, Ziv Y, Schwartz A, Landa G, Talpalar AE, Pluchino S, et al. Microglia activated  
335 by IL-4 or IFN-gamma differentially induce neurogenesis and oligodendrogenesis from adult  
336 stem/progenitor cells. *Mol Cell Neurosci*. 2006;31(1):149-60. Epub 20051116. doi:  
337 10.1016/j.mcn.2005.10.006.
- 338 13.Albini A, Marchisone C, Del Grosso F, Benelli R, Masiello L, Tacchetti C, et al. Inhibition of  
339 angiogenesis and vascular tumor growth by interferon-producing cells: A gene therapy  
340 approach.*Am J Pathol*.2000;156(4):1381-93.doi: 10.1016/s0002-9440(10)65007-9.
- 341 14.Wang S, Zhang H, Xu Y. Crosstalk between microglia and T cells contributes to brain damage  
342 and recovery after ischemic stroke. *Neurol Res*. 2016;38(6):495-503. Epub 20160531. doi:  
343 10.1080/01616412.2016.1188473.
- 344 15.Cramer JV, Benakis C, Liesz A. T cells in the post-ischemic brain: Troopers or paramedics?J  
345 *Neuroimmunol*. 2019;326:33-7. Epub 20181113. doi: 10.1016/j.jneuroim.2018.11.006.
- 346 16.Jickling GC, Liu D, Ander BP, Stamova B, Zhan X, Sharp FR. Targeting neutrophils in ischemic  
347 stroke: translational insights from experimental studies. *J Cereb Blood Flow Metab*.




- 348 2015;35(6):888-901. Epub 20150325. doi: 10.1038/jcbfm.2015.45.  
349 17.Maestroni GJ. Sympathetic nervous system influence on the innate immune response. *Ann N Y*  
350 *Acad Sci.* 2006;1069:195-207. doi: 10.1196/annals.1351.017.  
351 18.Yuan M, Han B, Xia Y, Liu Y, Wang C, Zhang C. Augmentation of peripheral lymphocyte-  
352 derived cholinergic activity in patients with acute ischemic stroke. *BMC Neurol.* 2019;19(1):236.  
353 Epub 20191015. doi: 10.1186/s12883-019-1481-5.  
354 19.Prass K, Meisel C, Höflich C, Braun J, Halle E, Wolf T, et al. Stroke-induced immunodeficiency  
355 promotes spontaneous bacterial infections and is mediated by sympathetic activation reversal by  
356 poststroke T helper cell type 1-like immunostimulation. *J Exp Med.* 2003;198(5):725-36. Epub  
357 20030825. doi: 10.1084/jem.20021098.  
358 20.Sekiya T, Yoshimura A. In Vitro Th Differentiation Protocol. *Methods Mol Biol.*  
359 2016;1344:183-91. doi: 10.1007/978-1-4939-2966-5\_10.  
360 21.Shapouri-Moghaddam A, Mohammadian S, Vazini H, Taghadosi M, Esmaeili SA, Mardani F,  
361 et al. Macrophage plasticity, polarization, and function in health and disease. *J Cell Physiol.*  
362 2018;233(9):6425-40. Epub 20180301. doi: 10.1002/jcp.26429.  
363 22.Tschoe C, Bushnell CD, Duncan PW, Alexander-Miller MA, Wolfe SQ. Neuroinflammation  
364 after Intracerebral Hemorrhage and Potential Therapeutic Targets. *J Stroke.* 2020;22(1):29-46. Epub  
365 20200131. doi: 10.5853/jos.2019.02236.  
366  
367  
368  
369





medRxiv preprint doi: <https://doi.org/10.1101/2023.10.16.23297078>; this version posted October 16, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).






medRxiv preprint doi: <https://doi.org/10.1101/2023.10.16.23297078>; this version posted October 16, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).



**Fig 1**



medRxiv preprint doi: <https://doi.org/10.1101/2023.10.16.23297078>; this version posted October 16, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).








Fig 2



medRxiv preprint doi: <https://doi.org/10.1101/2023.10.16.23297078>; this version posted October 16, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).



**Fig 7**